Insight Capital Research & Management Inc. bought a new stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 2,870 shares of the exchange traded fund’s stock, valued at approximately $248,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of XBI. Wechter Feldman Wealth Management Inc. lifted its holdings in SPDR S&P Biotech ETF by 0.4% in the second quarter. Wechter Feldman Wealth Management Inc. now owns 3,172 shares of the exchange traded fund’s stock valued at $245,000 after acquiring an additional 12 shares during the period. Newman Dignan & Sheerar Inc. lifted its holdings in SPDR S&P Biotech ETF by 0.6% in the second quarter. Newman Dignan & Sheerar Inc. now owns 8,260 shares of the exchange traded fund’s stock valued at $638,000 after acquiring an additional 50 shares during the period. Willingdon Wealth Management lifted its holdings in SPDR S&P Biotech ETF by 1.8% in the second quarter. Willingdon Wealth Management now owns 6,541 shares of the exchange traded fund’s stock valued at $505,000 after acquiring an additional 118 shares during the period. Bank of New York Mellon Corp lifted its holdings in SPDR S&P Biotech ETF by 1.0% in the second quarter. Bank of New York Mellon Corp now owns 19,274 shares of the exchange traded fund’s stock valued at $1,488,000 after acquiring an additional 197 shares during the period. Finally, Vestor Capital LLC lifted its holdings in SPDR S&P Biotech ETF by 0.5% in the second quarter. Vestor Capital LLC now owns 38,663 shares of the exchange traded fund’s stock valued at $2,984,000 after acquiring an additional 208 shares during the period.

Shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) traded up $1.38 during trading hours on Wednesday, reaching $83.07. The company’s stock had a trading volume of 4,911,900 shares, compared to its average volume of 4,244,431. SPDR S&P Biotech ETF has a one year low of $58.66 and a one year high of $88.98.

ILLEGAL ACTIVITY NOTICE: “Insight Capital Research & Management Inc. Invests $248,000 in SPDR S&P Biotech ETF (XBI) Stock” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.watchlistnews.com/insight-capital-research-management-inc-invests-248000-in-spdr-sp-biotech-etf-xbi-stock/1761982.html.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.